Cobra Biologics and Alligator Bioscience have entered into a manufacturing services and supply agreement for the production of monoclonal antibody drug product for preclinical and Phase I and II trials.
Cobra will provide cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP supplies, as well as stability studies and QP release for clinical trials.
Alligator will utilize the maxXpress service, which combines the UCOE protein expression technology with Cobra’s cell line development team and the Cello robotic clone selection system, designed to enable rapid clone selection and production of the monoclonal antibody.
Peter Coleman, chief executive officer of Cobra Biologics, said, "Having been through a rigorous selection process, we are very pleased to have been chosen by Alligator. We believe that our comprehensive service offering, right from our excellent cell line development capability through to fill/finish at our recently acquired Matfors facility (Sweden) enabled us to win this important program with Alligator in a highly competitive market place. We look forward to building a lasting relationship with Alligator Bioscience.”